Lapatinib-d4

Modify Date: 2024-09-08 18:13:33

Lapatinib-d4 structure	Common Name	Lapatinib-d4
	CAS Number	1184263-99-7	Molecular Weight	585.08
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₉H₂₂D₄ClFN₄O₄S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Lapatinib-d4

Lapatinib-d4 (GW572016-d4) is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1][2].

Name	Lapatinib-d4

Description	Lapatinib-d4 (GW572016-d4) is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR Signaling Pathways >> Apoptosis >> Ferroptosis Signaling Pathways >> Autophagy >> Autophagy
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94.

Molecular Formula	C₂₉H₂₂D₄ClFN₄O₄S
Molecular Weight	585.08

Lapatinib-d4

Use of Lapatinib-d4

Names

Lapatinib-d4 Biological Activity

Chemical & Physical Properties